drugset / Trial / NCT01005355

Study of IMC-1121B in Patients With Advanced Solid Tumors

NCT01005355

Phase 1 Completed 15 enrolled Eli Lilly and Company Parexel · collab
NaSingle-groupOpen-labelTreatment

Summary

This trial is testing the investigational drug IMC-1121B administered to Japanese participants with advanced solid tumors who have not responded to standard therapy or for whom no standard therapy is available. The rationale for performing this trial is to establish the safety profile and the pharmacokinetics of IMC-1121B.

Timeline

Start
2009-09
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramucirumab Monoclonal antibody 6 mg/kg Intravenous
Subject Ramucirumab Monoclonal antibody 8 mg/kg Intravenous
Subject Ramucirumab Monoclonal antibody 10 mg/kg Intravenous

Indications